Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Pemetrexed: A Multi-Targeted Antifolate for Cancer Chemot...

    2025-11-30

    Pemetrexed: A Multi-Targeted Antifolate for Cancer Chemotherapy Research

    Executive Summary: Pemetrexed (LY-231514) is a multi-targeted antifolate antimetabolite that inhibits thymidylate synthase, dihydrofolate reductase, and key enzymes in nucleotide biosynthesis, disrupting DNA/RNA synthesis in proliferating tumor cells (Borchert et al. 2019). It demonstrates robust in vitro antiproliferative activity at 0.0001–30 μM and in vivo synergy with immunomodulation in murine mesothelioma models. Pemetrexed is a first-line component in non-small cell lung carcinoma and malignant mesothelioma chemotherapy protocols (APExBIO). Its broad mechanistic scope enables research into folate metabolism, chemoresistance, and DNA repair vulnerabilities. This article provides structured evidence and workflow guidance for deploying pemetrexed in preclinical oncology research.

    Biological Rationale

    Pemetrexed (pemetrexed disodium, LY-231514) is a synthetic antifolate antimetabolite. It inhibits several folate-dependent enzymes necessary for de novo purine and pyrimidine biosynthesis. These pathways are essential for DNA and RNA synthesis in proliferating cells. Tumor cells often have increased nucleotide demand due to rapid division, rendering them susceptible to antifolate agents (Borchert et al. 2019). In malignant mesothelioma and non-small cell lung carcinoma, these vulnerabilities are clinically exploited by pemetrexed-based chemotherapies. Additionally, defects in homologous recombination repair (HRR) and DNA damage response pathways (termed BRCAness) in certain tumors increase dependence on nucleotide biosynthesis and alternative DNA repair, further sensitizing them to antifolates and combination regimens (Borchert et al. 2019).

    Mechanism of Action of Pemetrexed

    Pemetrexed competitively inhibits multiple enzymes critical for folate metabolism and nucleotide biosynthesis, including:

    • Thymidylate synthase (TS): Blocks dTMP synthesis, depleting thymidine pools required for DNA replication.
    • Dihydrofolate reductase (DHFR): Prevents tetrahydrofolate regeneration, impairing methylation and purine/pyrimidine synthesis.
    • Glycinamide ribonucleotide formyltransferase (GARFT): Inhibits purine biosynthesis at the GAR step.
    • Aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT): Further impairs purine nucleotide formation.

    This multi-targeted inhibition disrupts both purine and pyrimidine synthesis, leading to cell cycle arrest and apoptosis in rapidly dividing tumor cells (APExBIO). The structure of pemetrexed, featuring a pyrrolo[2,3-d]pyrimidine core, enhances its antifolate potency compared to earlier agents. Cellular uptake is mediated via the reduced folate carrier and membrane folate receptors, with intracellular polyglutamation increasing retention and efficacy.

    Evidence & Benchmarks

    • Pemetrexed inhibits proliferation of tumor cell lines in vitro at concentrations ranging from 0.0001 to 30 μM after 72-hour incubation (APExBIO).
    • Chemotherapy regimens combining pemetrexed and cisplatin represent the current standard of care for unresectable malignant pleural mesothelioma, with response rates around 40% (Borchert et al. 2019).
    • In vivo, intraperitoneal administration of pemetrexed at 100 mg/kg in murine mesothelioma models produces antitumor effects and synergizes with regulatory T cell blockade (APExBIO).
    • Gene expression profiling identifies a subset (up to 10%) of mesothelioma patients with BRCAness phenotype, potentially impacting chemosensitivity and repair pathway dependence (Borchert et al. 2019).
    • Gene markers such as AURKA, RAD50, and DDB2 are prognostic in malignant pleural mesothelioma and may modulate pemetrexed response (Borchert et al. 2019).

    For a forward-looking overview of translational pemetrexed workflows, see "Pemetrexed and the Next Wave of Translational Cancer Research", which discusses actionable experimental guidance beyond the product-focused scope of this dossier.

    Applications, Limits & Misconceptions

    Pemetrexed is employed as a research tool in cancer biology for:

    • Modeling chemotherapeutic responses in non-small cell lung carcinoma and mesothelioma.
    • Investigating folate metabolism and nucleotide biosynthesis inhibition.
    • Studying mechanisms of chemoresistance, DNA repair, and synthetic lethality (e.g., BRCAness, PARP inhibition synergies).
    • Optimizing combination regimens with platinum agents or immunotherapy.

    For detailed protocols and troubleshooting advice, see "Pemetrexed in Cancer Research: Advanced Workflows & Troubleshooting", which this article extends by focusing on mechanistic context and evidence synthesis rather than step-by-step experimental design.

    Common Pitfalls or Misconceptions

    • Pemetrexed is not effective in tumors with primary resistance to antifolates due to impaired drug uptake or rapid efflux.
    • Excess folic acid supplementation may antagonize pemetrexed's activity in vitro; levels should be carefully controlled.
    • Not all HRR-deficient (BRCAness) tumors show enhanced pemetrexed sensitivity; other repair pathways may compensate (Borchert et al. 2019).
    • Pemetrexed is insoluble in ethanol and should not be prepared in this solvent; DMSO or water are preferred.
    • In vivo efficacy and toxicity are species- and model-dependent; murine dosages (e.g., 100 mg/kg i.p.) do not extrapolate directly to other organisms (APExBIO).

    Workflow Integration & Parameters

    Pemetrexed (A4390, APExBIO) is supplied as a solid with a molecular weight of 471.37 g/mol. It is soluble in DMSO (≥15.68 mg/mL with gentle warming and ultrasound) or water (≥30.67 mg/mL). Storage at -20°C is recommended for stability. For in vitro studies, effective antiproliferative concentrations range from 0.0001 to 30 μM, with typical incubation times of 72 hours. For in vivo mouse models, 100 mg/kg intraperitoneal dosing has been used in combination with immunomodulators. Researchers should calibrate dosing and exposure based on cell line, assay conditions, and experimental goals. For advanced application strategies, see "Pemetrexed in Translational Oncology: Mechanistic Leverage", which details systems biology approaches that complement the mechanistic benchmarks provided here.

    Conclusion & Outlook

    Pemetrexed is a validated, multi-targeted antifolate agent with broad applications in cancer biology, particularly for probing folate metabolism, nucleotide biosynthesis, and DNA repair vulnerabilities. Its robust in vitro and in vivo performance, combined with mechanistic versatility, make it an essential tool for translational and preclinical oncology research. Ongoing gene expression profiling and combination therapy studies continue to clarify the boundaries and expand the utility of pemetrexed in the era of precision medicine. For product specifications, refer to Pemetrexed (A4390) from APExBIO.